

TITLE PAGE

Original Article

**Genetic analyses identify *GSDMB* associated with asthma severity, exacerbations, and antiviral pathways**

Xingnan Li, PhD, MS,<sup>a</sup> Stephanie A. Christenson, MD,<sup>b</sup> Brian Modena, MD,<sup>c</sup> Huashi Li, MS,<sup>a</sup> William W. Busse, MD,<sup>d</sup> Mario Castro, MD,<sup>e</sup> Loren C. Denlinger, MD, PhD,<sup>d</sup> Serpil C. Erzurum, MD,<sup>f</sup> John V. Fahy, MD,<sup>b</sup> Benjamin Gaston, MD,<sup>g</sup> Annette T. Hastie, PhD,<sup>h</sup> Elliot Israel, MD,<sup>i</sup> Nizar N. Jarjour, MD,<sup>d</sup> Bruce D. Levy, MD,<sup>i</sup> Wendy C. Moore, MD,<sup>h</sup> Prescott G. Woodruff, MD,<sup>b</sup> Naftali Kaminski, MD,<sup>j</sup> Sally E. Wenzel, MD,<sup>k</sup> Eugene R. Bleeker, MD,<sup>a</sup> Deborah A. Meyers, PhD,<sup>a</sup> for the NHLBI Severe Asthma Research Program (SARP)

<sup>a</sup>Division of Genetics, Genomics and Precision Medicine, Department of Medicine, University of Arizona, Tucson, Arizona, USA; <sup>b</sup>Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California at San Francisco, San Francisco, California, USA; <sup>c</sup>Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado, USA; <sup>d</sup>Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA; <sup>e</sup>Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, Kansas, USA; <sup>f</sup>Lerner Research Institute and the Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA; <sup>g</sup>Wells Center for Pediatric Research and Riley Hospital for Children, Indiana University,

This is the author's manuscript of the article published in final edited form as:

Li, X., Christenson, S. A., Modena, B., Li, H., Busse, W. W., Castro, M., Denlinger, L. C., Erzurum, S. C., Fahy, J. V., Gaston, B., Hastie, A. T., Israel, E., Jarjour, N. N., Levy, B. D., Moore, W. C., Woodruff, P. G., Kaminski, N., Wenzel, S. E., Bleeker, E. R., & Meyers, D. A. (2020). Genetic analyses identify *GSDMB* associated with asthma severity, exacerbations, and antiviral pathways. *Journal of Allergy and Clinical Immunology*. <https://doi.org/10.1016/j.jaci.2020.07.030>

Indianapolis, Indiana, USA; <sup>h</sup>Department of Medicine, Wake Forest School of Medicine,  
Winston-Salem, North Carolina, USA; <sup>i</sup>Division of Pulmonary and Critical Care Medicine,  
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;  
<sup>j</sup>Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine,  
Yale School of Medicine, New Haven, Connecticut, USA; <sup>k</sup>Department of Environmental and  
Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;

**Corresponding author and request for reprints:**

Xingnan Li, PhD, MS  
Division of Genetics, Genomics and Precision Medicine  
Department of Medicine  
University of Arizona  
1230 N Cherry Avenue  
PO Box 210242  
Tucson, AZ 85719  
Telephone: 520-626-2905  
Fax: 520-626-1894  
Email: [lixingnan1@deptofmed.arizona.edu](mailto:lixingnan1@deptofmed.arizona.edu)

**Declaration of all sources of funding:** SARP cross-sectional cohort was supported by NIH  
grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349,  
UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762.  
SARP longitudinal cohort was funded by the NHLBI U10 HL109172, HL109168, HL109152,



HL109257, HL109046, HL109250, HL109164, and HL109086. Genetic studies for SARP cross-sectional cohort were funded by NIH HL87665 and Go Grant RC2HL101487. SARP whole-genome sequencing was supported by NHLBI Trans-Omics for Precision Medicine (TOPMed) X01 grant.

**Disclosure of potential conflict of interest:** B. Modena reports grants from NHLBI, personal fees from Sanofi, Regeneron, GSK, Circassia, and AstraZeneca. W. W. Busse has received consulting fees from AstraZeneca, Genentech, Regeneron, Novartis, Sanofi, and GlaxoSmithKline. M. Castro receives University Grant Funding from NIH, American Lung Association, and PCORI, receives Pharmaceutical Grant Funding from AstraZeneca, Chiesi, Novartis, GSK, and Sanofi-Aventis, serves as a consultant for Genentech, Theravance, VIDA, Teva, Sanofi-Aventis and also a speaker for AstraZeneca, Genentech, GSK, Regeneron, Sanofi, Teva, and receives Royalties from Elsevier. A. T. Hastie reports grants from NIH and grant support from Genentech during the conduct of the study. B. D. Levy reports grants from NHLBI, personal fees from AstraZeneca, Bayer, Gossamer Bio, Merck, Nacion Therapeutics, Pieris Pharmaceuticals, Teva Pharmaceuticals, SRA, and Sanofi. P. G. Woodruff reports personal fees from Sanofi, Glenmark Pharmaceuticals, Theravance, GSK, NGM Pharma, Amgen, and Genentech. S. E. Wenzel has consulted for AstraZeneca, Genentech, GSK, Sanofi-Aventis in the last 3 yrs, in matters unrelated to the content of this manuscript, participated in multicenter clinical trial for AstraZeneca, GSK, Novartis and Sanofi Aventis in the last 3 yrs, unrelated to this manuscript, and received financial support for the last 2 yrs of SARP from an unrestricted grant from Boehringer-Ingelheim. E. R. Bleeker has performed clinical trials through his employer, Wake Forest School of Medicine and University of Arizona, for AstraZeneca,

70 MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme, and  
71 has also served as a paid consultant for ALK-Abello, AstraZeneca, MedImmune, Glaxo Smith  
72 Kline, Novartis, Regeneron, Sanofi Genzyme, and TEVA, outside the submitted work. All other  
73 authors have nothing to disclose.

**ABSTRACT**

Background: Chr17q12-21.2 region is the strongest and most consistently associated region with asthma susceptibility. The functional genes or single nucleotide polymorphisms (SNPs) are not obvious due to linkage disequilibrium.

Objectives: Whole-genome sequence and RNAseq from human bronchial epithelial cells (BEC) were comprehensively investigated to dissect functional genes/SNPs for asthma severity in the Severe Asthma Research Program (SARP).

Methods: eQTL analysis (n=114), correlation analysis (n=156) of gene expression and asthma phenotypes, and pathway analysis were performed in BEC and replicated. Genetic association for asthma severity (426 severe vs. 531 non-severe asthma) and longitudinal asthma exacerbations (n=273) was performed.

Results: Multiple SNPs in *GSDMB* associated with asthma severity (odds ratio>1.25) and longitudinal asthma exacerbations ( $p<0.05$ ). eQTL analyses identified multiple SNPs associated with expression levels of *PGAP3*, *GSDMB*, or *GSDMA* ( $3.1\times10^{-9}<p<1.8\times10^{-4}$ ). Higher expression levels of *GSDMB* correlated with asthma and greater number of exacerbations ( $p<0.05$ ). Expression levels of *GSDMB* correlated with genes involved in interferon signaling, MHC class I antigen presentation, and immune system pathways (FDR- $p<0.05$ ). rs1031458 and rs3902920 in *GSDMB* colocalized with interferon regulatory factor (IRF) binding sites and associated with *GSDMB* expression, asthma severity, and asthma exacerbations ( $p<0.05$ ).

97 Conclusions: By using a unique set of gene expression data from lung cells obtained using  
98 bronchoscopy from comprehensively characterized asthma subjects, we show that SNPs in  
99 *GSDMB* associated with asthma severity, exacerbations, and *GSDMB* expression levels.  
100 Furthermore, its expression levels correlated with asthma exacerbations and antiviral pathways.  
101 Thus, *GSDMB* is a functional gene for both asthma susceptibility and severity.

**Key Messages**

• SNPs in *GSDMB* were associated with asthma, asthma severity, asthma exacerbations, and *GSDMB* expression levels, and its expression levels were correlated with asthma, asthma exacerbations, and antiviral pathways.

• SNPs in *PGAP3-ERBB2*, *ZBP2-GSDMB-ORMDL3*, and *GSDMA* regions were associated with the expression levels of *PGAP3*, *GSDMB*, and *GSDMA*, respectively; SNPs in *IKZF3* were associated with the expression levels of *PGAP3*, *GSDMB*, or *GSDMA*.

• SNPs identified by GWAS of asthma or autoimmune diseases (AD) were also eQTL SNPs for *PGAP3*, *GSDMB*, or *GSDMA*, but showed opposite effect alleles between asthma and AD.

**Capsule summary**

By using a unique dataset of gene expression from lung cells of asthmatics, we show strong evidence for *GSDMB* as a gene for asthma severity and asthma exacerbations probably through antiviral pathways.

**Key words**

Antiviral pathways; asthma exacerbations; asthma severity; eQTL; genetics; *GSDMA*; *GSDMB*; *PGAP3*; whole-genome sequence; RNAseq

**Abbreviations used**

ACQ-6: asthma control questionnaire-6

AD: autoimmune diseases

BEC: bronchial epithelial cells

- 125 CD: Crohn's disease
- 126 eQTL: expression quantitative trait loci
- 127 ER: emergency room
- 128 FDR: false discovery rate
- 129 *GSDMA*: gasdermin A
- 130 *GSDMB*: gasdermin B
- 131 GTEx: Genotype-Tissue Expression database
- 132 GWAS: genome-wide association study
- 133 HRV: human rhinovirus
- 134 IBD: inflammatory bowel disease
- 135 LD: linkage disequilibrium
- 136 MAF: minor allele frequency
- 137 MS: multiple sclerosis
- 138 *ORMDL3*: ORMDL sphingolipid biosynthesis regulator 3
- 139 *PGAP3*: post-GPI attachment to proteins 3
- 140 PBCh: primary biliary cholangitis
- 141 PBCi: primary biliary cirrhosis
- 142 QC: quality control
- 143 RA: rheumatoid arthritis
- 144 RNAseq: RNA sequence
- 145 SARP: Severe Asthma Research Program
- 146 SLE: systemic lupus erythematosus
- 147 SNP: Single nucleotide polymorphism

- 148 SS: systemic sclerosis
- 149 TOPMed: Trans-Omics for Precision Medicine
- 150 T1D: type I diabetes
- 151 UC: ulcerative colitis
- 152 WGS: whole-genome sequence

## INTRODUCTION

Asthma is a common inflammatory airway disease. *ORMDL3* in chr17q12-21.2 region was the first gene identified through genome-wide association study (GWAS) of asthma.<sup>1</sup> Since then, GWAS, candidate gene replication, and gene expression studies have consistently identified or confirmed SNPs in multiple genes in this region that are associated with asthma susceptibility, including *PGAP3*,<sup>2-4</sup> *ERBB2*,<sup>5</sup> *IKZF3*,<sup>6-9</sup> *ZBP2*,<sup>10-11</sup> *GSDMB*,<sup>1,5,8,12-20</sup> *ORMDL3*,<sup>11,21-25</sup> and *GSDMA*.<sup>9,14-15,26</sup> SNPs in *IKZF3*,<sup>27</sup> *ZBP2*,<sup>28</sup> *GSDMB*,<sup>10,29-30</sup> and *PSMD3*<sup>29</sup> have also been associated with allergic responses. However, partially due to linkage disequilibrium (LD), it has been difficult to determine the specific genes or SNPs responsible for those association. In addition, most published GWAS of asthma has tested the association of SNPs with asthma susceptibility (mild or severe asthma vs. healthy controls), not asthma severity. To analyze asthma severity, we performed a genetic association analysis for severe asthma compared to non-severe asthma and asthma exacerbations longitudinally over a 3 year period.

Autoimmune diseases (AD) arise from abnormal immune responses to self-antigens. SNPs in *ERBB2*,<sup>31</sup> *IKZF3*,<sup>32-44</sup> *ZBP2*,<sup>45-46</sup> *GSDMB*,<sup>47-58</sup> and *GSDMA*<sup>59-60</sup> have been associated with a variety of AD. In a previously published GWAS, we were the first to report that the opposite risk alleles in *IL13*, *TNIP1*, *HLA-DRA*, and *GSDMB* associated with asthma and AD.<sup>61</sup> In this study, we comprehensively compared all the GWAS-identified SNPs associated with asthma, allergy, and AD in chr17q12-21 region to reveal genetic effects on the immunopathogenesis of asthma, allergy, and AD.



In a recent review, genetic association, expression quantitative trait loci (eQTL), and epigenetics of 17 SNPs in chr17q12-21.2 region with asthma have been summarized.<sup>62</sup> Proximal (*PGAP3-ERBB2*), core (*IKZF3-ZPBP2-GSDMB-ORMDL3*), and distal (*GSDMA*) regions have been suggested as independent regions associated with asthma.<sup>62</sup>

In order to delineate the functional genes/SNPs for asthma severity in this region, we utilized a unique dataset of lung gene expression data obtained from bronchial brushing during investigational bronchoscopy in extensively characterized patients with current asthma plus healthy controls. We hypothesize that combining SNP with RNA gene expression data from lung cells of asthmatics, we will be able to determine the functional asthma genes/SNPs in this complicated chromosomal region.

## METHODS

### Study subjects

SARP is a currently active multicenter program funded for the last 18 years by the NHLBI. Mild to severe subjects with asthma (enriched for severe) and a subset of controls have been extensively studied using standardized protocols. The earlier SARP cohort was cross-sectional (n=1,644). In a subset of subjects with mild to severe asthma, RNA was isolated from epithelial cells (BEC; n=155) that were obtained from brush biopsies (Table I and Table E1).<sup>63-65</sup> The current SARP cohort is an ongoing longitudinal study (n=714).<sup>66-68</sup> Bronchoscopy was performed on a subset of the longitudinal cohort to obtain epithelial cells from brush biopsies (n=156) for RNAseq (Table I and Table E1). All studies were approved by the appropriate institutional review board at the participating sites including informed consent.

### Statistical analysis

Selection of SNPs and RNAseq Data. Whole genome sequencing (WGS) in SARP (n=1,888; version Freeze 6; dbGaP accession: phs001446) was performed through NHLBI-sponsored TOPMed Program ([www.nhlbiwgs.org](http://www.nhlbiwgs.org)). Standard quality control (QC) was performed. All SNPs in chr17q12-21.2 region were extracted (hg38: *PPP1R1B* to *CSF3*; chr17:39,626,924-40,017,813) in the longitudinal cohort with WGS using PLINK 1.9 software,<sup>69</sup> and further QC were performed as described.<sup>61,70</sup> Similarly, SNPs were extracted from the cross-sectional cohort with GWAS data and imputed based on TOPMed reference panel using the Michigan Imputation Server.<sup>71</sup>

RNAseq data from BEC in the longitudinal cohort were extracted for 14 candidate genes (except for *ZPBP2* and *LRRC3C* which failed QC) in chr17q12-21.2 region. In brief, Illumina HiSeq RNAseq reads were quality filtered and mapped to human genome hg38 using STAR package.<sup>72</sup> Read counts were regularized logarithm transformed using DESeq2 package.<sup>73</sup> The RNAseq data will be deposited and accessible through GEO ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)). Agilent Whole Human Genome Microarray expression data of these 16 genes were extracted from BEC in the cross-sectional cohort as described.<sup>74-75</sup> The microarray expression data have been deposited and can be accessed through GSE63142 and GSE43696.<sup>74,76-77</sup>

Genetic Association Analysis. Logistic or linear regression, assuming a genetic additive model, was used for genetic association analysis of asthma severity (426 severe asthma vs. 531 non-severe asthma) and the number of exacerbations (n=273) due to asthma in three years in non-Hispanic White adults (age $\geq$ 12 years old) in the longitudinal cohort (Table I), adjusted for age, sex, and the first five components from the multidimensional scaling analysis of genome.

We first investigated a set of 48 candidate SNPs identified by previous GWAS of asthma, allergy, and AD (NHGRI-EBI GWAS catalog;<sup>78</sup> [www.ebi.ac.uk/gwas/](http://www.ebi.ac.uk/gwas/)) incorporated in UCSC genome browser ([genome.ucsc.edu](http://genome.ucsc.edu); accessed on August 12, 2019)<sup>79</sup> for association with asthma severity and longitudinal exacerbations in SARP (Figure 1). To reduce multiple tests due to SNPs with strong LD, the numbers of independent tests were calculated using GEC.<sup>80</sup> 14.4 independent tests of 48 candidate SNPs were indicated by GEC, and thus SNPs with p-value $<0.0035$  (0.05/14.4 tests) were considered significant. SNPs with p-value $<0.05$  were considered as nominally significant. From all sequenced SNPs in the chr17q12-21.2 region, we extracted 1,266 common

SNPs ( $MAF \geq 0.01$ ) to test for association and  $p\text{-value} < 0.05$  was considered as nominally significant due to relatively small sample size. Note that all of the 48 candidate SNPs were included in the set of 1,266 common SNPs. LD was estimated with 95% confidence intervals of  $D'$  to define LD blocks and LD plots of candidate SNPs in chr17q12-21.2 region were generated separately for 1,016 non-Hispanic Whites and 622 African Americans (Table I) using Haploview.<sup>81</sup>

**eQTL Analysis.** A linear additive genetic model was used to test the association between SNPs and inverse normalized expression data as described before.<sup>74-75</sup> The longitudinal and cross-sectional cohorts were used as discovery and replication datasets, respectively (Figure 1). Significant eQTL SNPs identified in the lung tissue ( $n=383$ ) from Genotype-Tissue Expression (GTEx) database<sup>26</sup> were also evidence for replication (Figure 1). In the longitudinal cohort with WGS and RNAseq in BEC ( $n=114$ ), 252.6 independent tests of 862 common SNPs ( $MAF \geq 0.05$ ) in chr17q12-21.2 region were indicated by GEC,<sup>80</sup> and thus, SNPs with  $p\text{-value} < 1.98 \times 10^{-4}$  ( $0.05/252.6$  tests) were considered as significant eQTL SNPs. SNPs with  $p\text{-value} < 0.05$  were considered as nominally significant. Conditional eQTL analysis of *PGAP3*, *GSDMB*, and *GSDMA* in the longitudinal cohort was performed to identify independent eQTL SNPs by stepwise adjusting the most significant eQTL SNP.

**Colocalization Analysis.** To test whether the same SNP ( $n=862$ ) is responsible for the genetic association of asthma severity and eQTL of *PGAP3*, *GSDMB*, or *GSDMA* in the longitudinal cohort (Figure 1), a Bayesian-based colocalization analysis was performed using coloc package.<sup>82</sup> A posterior probability of 75% or greater was considered as strong evidence of

colocalization. Colocalization analysis of SNPs associated with asthma severity or longitudinal asthma exacerbations and with gene expression of *PGAP3*, *GSDMB*, or *GSDMA* in the longitudinal cohort (Figure 1) was also performed through conditional eQTL analysis by adjusting the most significant SNP associated with asthma severity or longitudinal asthma exacerbations.

Correlation Analysis of Gene Expression and Asthma Phenotypes. Correlation analysis of gene expression and asthma-related phenotypes was performed as described (Figure 1).<sup>74-75</sup> In brief, a generalized linear model was used to test the correlation between expression levels of 16 candidate genes and asthma-related phenotypes with adjustment of age, sex, race (dummy variables for non-Hispanic Whites and African Americans), BMI, and batch effect. P-value<0.05 was considered as nominally significant.

Pathway Analysis. Correlation analysis of gene expression levels of 16,068 genes in the longitudinal cohort or 19,567 genes in the cross-sectional cohort was performed using Spearman's rank correlation. The genes with expression levels significantly correlated with *PGAP3*, *GSDMB*, or *GSDMA* ( $p<0.05/16,067=3.1\times10^{-6}$  in the longitudinal cohort and  $p<0.05/19,566=2.5\times10^{-6}$  in the cross-sectional cohort) were input into Reactome software for pathway analysis<sup>83</sup> (Figure 1). Enriched biological pathways were identified using a hypergeometric distribution test with false discovery rate (FDR) adjusted p-value<0.05.

IRF Binding Site Analysis. Interferon regulatory factor (IRF) binding sites were checked for *GSDMB* based on ENCODE database (Figure 1).<sup>84</sup> Genetic association and eQTL analyses were

277 performed for two common SNPs and four rare SNPs ( $MAF < 0.01$ ) in the identified IRF binding  
278 sites of *GSDMB*.

## RESULTS

### Genetic Association Analysis

16 candidate genes in chr17q12-21.2 region (Figure E1) were selected based on the published GWAS of asthma, allergy, or AD.<sup>78</sup> To elucidate shared genetic variants for immune diseases, 48 SNPs in this region identified through GWAS of asthma, allergy, and AD<sup>78-79</sup> or associated with asthma as reported by Stein *et al.*<sup>62</sup> were investigated (Table II).

Most of the SNPs previously associated with asthma susceptibility were associated with asthma severity at the nominal p-value of 0.05 (Table II). rs2305479 and rs62067034 in *GSDMB* were significantly associated with asthma severity after multiple-test adjustment (odds ratio=1.34;  $p=0.0029<0.0035$ ). When testing 1,266 common SNPs, several independent signals were associated with asthma severity though no SNP reached a more stringent significance ( $p<0.05/1266$ ) (Table E2), including five SNPs in *GSDMB* (odds ratio>1.3;  $p<0.0035$ ) with the risk alleles associated with increased *GSDMB* expression.

Most of the SNPs previously associated with asthma susceptibility were also associated with longitudinal asthma exacerbations at the nominal p-value of 0.05 (Table II). rs2517955 in *PGAP3* was significantly associated with longitudinal asthma exacerbations after multiple-test adjustment ( $p=0.0034$ ). When testing 1,266 common SNPs, several independent signals were associated with longitudinal asthma exacerbations though no SNP reached stringent significance ( $p<0.05/1266$ ) (Table E3), including four SNPs in *PGAP3-ERBB2* region ( $p<0.0035$ ) with the risk alleles associated with increased *PGAP3* expression.

Multiple SNPs in this region were associated with asthma, allergy, and AD, however, the risk alleles were opposite between asthma and AD (Table II). For example, the G allele of rs907092 in *IKZF3* was the risk allele for asthma ( $p < 5 \times 10^{-8}$ )<sup>7-8</sup> and asthma severity ( $p = 0.027$ ), and associated with higher expression levels of *GSDMB* ( $p = 3.7 \times 10^{-4}$ ) and *PGAP3* ( $p = 7.9 \times 10^{-4}$ ), but was the protective allele for primary biliary cholangitis (PBCh) ( $p < 5 \times 10^{-8}$ ).<sup>38</sup> The G allele of rs2305480 (a missense mutation in *GSDMB*) was the risk allele for asthma ( $p < 5 \times 10^{-8}$ ),<sup>14-15</sup> asthma severity ( $p = 0.015$ ), longitudinal asthma exacerbations ( $p = 0.0086$ ) and associated with higher expression levels of *GSDMB* ( $p = 2.5 \times 10^{-5}$ ), but was the protective allele for rheumatoid arthritis (RA) and ulcerative colitis (UC) ( $p < 5 \times 10^{-8}$ ).<sup>48,57</sup> The A allele of rs3894194 (a missense mutation in *GSDMA*) was the risk allele for asthma ( $p < 5 \times 10^{-8}$ )<sup>14-15</sup> and associated with lower expression levels of *GSDMA* ( $p = 4.3 \times 10^{-4}$ ), but was the protective allele for systemic sclerosis (SS) ( $p < 5 \times 10^{-8}$ ).<sup>59</sup> All 48 candidate SNPs identified by previous GWAS (Table II) were common SNPs ( $MAF \geq 0.01$ ), and thus, belonged to 1,266 common SNPs analyzed in this study. When ranking genetic association of asthma severity p-values of 1,266 SNPs, 35 (73%), 6 (13%), 3 (6%), and 4 (8%) of 48 candidate SNPs were distributed in the 1<sup>st</sup> to 4<sup>th</sup> quartile, respectively.

### eQTL Analysis and Colocalization Analysis

Expression of 14 genes (except *ZBP2* and *LRRC3C*) in the longitudinal cohort ( $n = 114$  BEC) and 16 gene in the cross-sectional cohort ( $n = 120$  BEC) passed QC (Table I and Table E1). LD pruning ( $r^2 \geq 0.8$ ) of 862 common SNPs ( $MAF \geq 0.05$ ) belonging to these 16 candidate genes generated 273 SNPs. The complete eQTL results of 862 SNPs were summarized in Table E4.



26 of 273 SNPs were significantly associated with the gene expression levels of *PGAP3*, *GSDMB*, or *GSDMA*, but not associated with the other genes in the longitudinal cohort (Table III and Table E4-E5). The eQTL findings of 26 SNPs in the longitudinal cohort were generally replicated in BEC in the cross-sectional cohort at nominal p-value of 0.05 (Table E6). Considering stringent replication ( $p < 0.05/26 = 1.9 \times 10^{-3}$ ), 16 of 26 SNPs in *PGAP3* or *GSDMB* were replicated in BEC in the cross-sectional cohort; 21 of 26 SNPs in *PGAP3*, *GSDMB*, or *GSDMA* were replicated in GTEx lung tissue (Table III); all together, 22 of 26 SNPs were replicated. Three and six LD blocks were formed for these 26 SNPs in non-Hispanic Whites and African Americans, respectively (Table III, Figure E2-E3). SNPs in *PPP1R1B*, *PGAP3*, and *ERBB2* were associated with *PGAP3* expression. SNPs in *IKZF3* region were associated with the expression levels of *PGAP3*, *GSDMB*, or *GSDMA*. SNPs in *ZBP2*, *GSDMB*, and *ORMDL3* were associated with *GSDMB* expression. SNPs in *GSDMA* were associated with *GSDMA* expression. Most of these 26 eQTL SNPs were associated with asthma severity or longitudinal asthma exacerbations at a nominal p-value of 0.05 (Table E7).

Five and six LD blocks were identified for 48 GWAS-identified SNPs in non-Hispanic Whites and African Americans, respectively (Table II, Figure E4-E5). Significant eQTL SNPs ( $p < 0.0035$ ) were associated with the expression levels of three genes (*PGAP3*, *GSDMB*, or *GSDMA*) in the longitudinal cohort and were generally replicated in the cross-sectional cohort at nominal p-value of 0.05 (Table II and Table E8). GTEx lung tissue eQTL in this region identified four genes (*PGAP3*, *GSDMB*, *ORMDL3*, and *GSDMA*) (Table II and III).

Conditional eQTL analysis was performed by stepwise adjusting the most significant eQTL SNP (Table E9), and indicated that two SNPs (rs2517954 in *PGAP3* and rs114211283 in *IKZF3*), two SNPs (rs11657449 in *ZPBP2-GSDMB* and rs3794712 in *PPP1R1B*), and one SNP (rs3859193 in *GSDMA*) were independent eQTL SNPs for *PGAP3*, *GSDMB*, and *GSDMA*, respectively.

Colocalization analysis<sup>82</sup> of the signals from genetic association of asthma severity and eQTL was performed, and indicated no significant colocalization SNP based on the criterion of posterior probability > 75% (Table E10). rs2517954 in *PGAP3*, rs11657449 in *ZPBP2-GSDMB*, and rs2941522 in *GRB7-IKZF3* were top colocalization SNPs for *PGAP3*, *GSDMB*, and *GSDMA*, respectively (Table E11). Colocalization analysis between SNPs associated with asthma severity or longitudinal asthma exacerbations and gene expression of *PGAP3*, *GSDMB*, and *GSDMA* was also performed through conditional eQTL analysis by adjusting the most significant SNP associated with asthma severity or longitudinal asthma exacerbations (Table E12, Table II). With adjustment of rs2952156 in *ERBB2*, rs2305479 in *GSDMB*, and rs3902025 in *GSDMA*, all eQTL SNPs for *PGAP3* (except for rs114211283 in *IKZF3*), for *GSDMB* (except for two SNPs in *PPP1R1B* and *ZPBP2-GSDMB*), and for *GSDMA* became non-significant. For example, the association between *GSDMB* expression and rs11657449 in *ZPBP2-GSDMB* or rs3794712 in *PPP1R1B* was weakened when adjusting for rs2305479, indicating that rs2305479 partly accounted for the eQTL association but not completely. In summary, the colocalization analyses did not show strong evidence for colocalization.

## Expression Analysis and Pathway Analysis

The risk alleles associated with asthma, asthma severity, and longitudinal asthma exacerbations were associated with higher expression levels of *PGAP3* and *GSDMB* or the lower expression levels of *GSDMA* (Table II), which indicated that expression levels of *PGAP3*, *GSDMB*, and *GSDMA* may be correlated with asthma phenotypes.

Correlation analysis of gene expression (*PGAP3*, *GSDMB*, and *GSDMA*) and asthma phenotypes was performed in BEC in the longitudinal cohort (n=156) and replicated in BEC (n=155) in the cross-sectional cohort (Table IV). Higher expression levels of *GSDMB* were correlated with asthma (p=0.05), greater number of exacerbations in the last 12 months (p=0.02), and higher reduction of ACQ-6 after steroid treatment (p=0.0008) in the longitudinal cohort. Higher expression levels of *GSDMB* were correlated with emergency room (ER) visits or hospitalizations due to asthma in the last 12 months (p=0.03) in the cross-sectional cohort. Other asthma-related phenotypes were not correlated with expression levels of *PGAP3*, *GSDMB*, or *GSDMA* (Table E13), except that higher expression levels of *GSDMB* were correlated with higher FeNO (p=0.03) in the longitudinal cohort. Although correlation analysis was focused on *PGAP3*, *GSDMB*, and *GSDMA*, the other 13 genes were also analyzed (Table E14-E15). Higher expression of *PNMT* and lower expression of *CSF3* were associated with asthma susceptibility in BEC in the longitudinal and cross-sectional cohorts.

Pathway analyses were performed on the genes with expression levels significantly correlated with *PGAP3*, *GSDMB*, or *GSDMA*. No biological pathways were identified for the genes correlated with *PGAP3* or *GSDMA* after FDR adjustment (data not shown). 435 and 677 genes were positively and negatively correlated with *GSDMB* ( $p < 3.1 \times 10^{-6}$ ) in BEC in the longitudinal

cohort, among which 636 genes were replicated in BEC in the cross-sectional cohort ( $p < 0.05$ ) (Table E16). Pathway analysis<sup>83</sup> was performed on 1,112 and 462 genes with expression levels significantly correlated with *GSDMB* expression in BEC in the longitudinal cohort ( $p < 3.1 \times 10^{-6}$ ) and cross-sectional cohort ( $p < 2.5 \times 10^{-6}$ ), respectively. Expression levels of *GSDMB* were correlated with genes involved in interferon alpha/beta/gamma signaling, MHC class I antigen presentation, and immune system pathways (FDR- $p < 0.05$ ) (Table V and Table E17).

### IRF Binding Site Analysis

Interferon regulatory factor (IRF) binding sites were checked for *GSDMB* and two regions were identified based on ENCODE database (Figure E6).<sup>84</sup> One IRF1/2 binding site was located at 5'UTR-exon 1-intron 1 region of *GSDMB* (Figure E7) and one IRF4 binding site was located at intron 2 of *GSDMB* (Figure E8). Two common SNPs and four rare SNPs were found in these two IRF binding sites based on SARP WGS (Table VI). Two common SNPs (rs1031458 and rs3902920) were associated with *GSDMB* expression, asthma severity, and longitudinal asthma exacerbations ( $p < 0.05$ ), making them potential functional SNPs.

T allele of rs1031458 or C allele of rs3902920 were risk alleles for asthma severity and longitudinal asthma exacerbations (Table VI), and they were also associated with early onset of asthma ( $p < 0.005$ ) (Table E18) especially atopic early onset (age onset of asthma  $< 6$  yrs) asthma ( $p < 0.00001$ ) (Table E19 and Figure 2). Similarly, most of the top 10 SNPs associated with asthma severity (including rs3902920; Table E2) were also associated with asthma severity in the subjects with early onset asthma (onset  $< 6$  yrs) (Table E20). rs1031458 and rs3902920 were in strong LD ( $r^2 \geq 0.8$ ) with multiple neighboring SNPs (Table II-III) in non-Hispanic Whites

(Table E21). In African Americans, rs1031458 and rs3902920 were in strong LD with three (rs921650, rs7216389, and rs201413617) and zero neighboring SNPs, respectively.

In summary, by using a unique set of gene expression data from lung cells of asthmatics obtained using investigative bronchoscopy and by performing comprehensive genetic association, expression correlation, eQTL, and pathway analyses, we have narrowed down chr17q12-21.2 region (16 candidate genes; 390 kbp) to two SNPs in *GSDMB* associated with asthma severity and asthma exacerbations potentially through antiviral pathways (Figure 1).

## DISCUSSION

Almost all the SNPs identified by previous GWAS in *GSDMB* now show to be associated with asthma severity and longitudinal asthma exacerbations, indicating that SNPs in *GSDMB* are associated with asthma susceptibility, asthma severity, and asthma exacerbations. Asthma and AD share extensive immunological pathways, however, the risk alleles of the same associated SNPs in this region are consistently opposite for asthma and AD, which may indicate distinct immunopathogenesis processes. In addition to SNPs with  $MAF \geq 0.01$ , we also investigated rare SNPs ( $MAF < 0.01$ ;  $n=4,006$ ) for association with asthma severity. 14 rare SNPs were associated with asthma severity at nominal p-value of 0.05 with large effect size ( $2.9 < \text{odds ratio} < 12$ ) (Table E22). Replication of these rare SNPs is needed in larger cohorts with sequence data and asthma phenotypes. In conclusion, findings from genetic association of asthma susceptibility, asthma severity, and asthma exacerbations in this region are generally consistent, however, genetic association analysis can not narrow down the 16 candidate genes due to strong and complicated LD structure in this region.

Gene expression is dependent on cell type or tissue, time, and environmental factors such as disease status. It is critical that cells are obtained from the appropriate organ (lung for asthma) and from living subjects with the disease being investigated instead of from surgical specimens (usually from cancer patients) or autopsy specimens. Even findings of eQTL analyses in lung cells are not always consistent (Table E23). The most significant eQTL genes were *GSDMA* followed by *GSDMB* and *ORMDL3* in two eQTL studies in lung tissue.<sup>26,85</sup> Nicodemus-Johnson *et al.* identified *ORMDL3* but not *GSDMB* in an eQTL analysis in BEC.<sup>4</sup> Our eQTL analysis in BEC in both longitudinal and cross-sectional cohorts<sup>74</sup> identified *GSDMB* but not *ORMDL3*.

Similarly, a recent genetic association and eQTL study has shown that eQTL SNPs for *GSDMB* (but not *ORMDL3*) in BEC play a major role in childhood asthma in African Americans.<sup>86</sup> BEC obtained from brush biopsies are mainly composed of epithelial cells, although small proportion of basal cells and immune cells also exist. A flow cytometry study showed that 95% to 97% of the cells from bronchial brushings were epithelial cells.<sup>87</sup> In this study, cell populations were not available for every subject, and thus, were not adjusted. Future eQTL and expression analyses by adjusting cell composition or single-cell RNAseq may reveal interesting results.

SNPs in *PGAP3-ERBB2* region were associated with *PGAP3* expression and longitudinal asthma exacerbations. In a previous GWAS, rs2941504 in *PGAP3* has been associated with asthma.<sup>2</sup> Another GWAS has identified rs2952156 in *ERBB2* associated with asthma<sup>5</sup> and *PGAP3* expression in lung tissue.<sup>26</sup> Thus, SNPs in *PGAP3-ERBB2* are associated with asthma phenotypes by up-regulating *PGAP3* gene expression. The first GWAS of asthma has identified rs7216389 in *GSDMB* associated with childhood asthma and the expression levels of *ORMDL3* and *GSDMB* in lymphoblastoid cell lines.<sup>1</sup> In this study, rs7216389 was significantly associated with *GSDMB* expression ( $p=1.7 \times 10^{-4}$ ) but not *ORMDL3* ( $p=0.22$ ) in BEC. Thus, SNPs in *ZBP2-GSDMB-ORMDL3* are associated with asthma phenotypes by up-regulating *GSDMB* gene expression. rs3894194 in *GSDMA* has been associated with asthma<sup>14-15</sup> and the expression levels of *GSDMA* in lung tissue.<sup>26</sup> In this study, rs3894194 was significantly associated with *GSDMA* expression ( $p=4.3 \times 10^{-4}$ ). Thus, SNPs in *GSDMA* are associated with asthma phenotypes by down-regulating *GSDMA* gene expression. Interestingly, SNPs in *IKZF3* were not consistently associated with a specific gene expression, instead, associated with the expression levels of *PGAP3*, *GSDMB*, or *GSDMA*, which may indicate long-distance gene expression

regulation. Interaction between gene regulatory elements and genes shown by GeneHancer<sup>88</sup> also indicated *IKZF3* was involved in complicated long-distance regulation of *GSDMB*, *GSDMA*, *ORMDL3*, and *ERBB2* (Figure E9). In summary, our findings confirm the hypothesis that there are proximal, core, and distal regions independently associated with asthma.<sup>62</sup> In addition, *IKZF3* forms a long-distance regulation region. More importantly, we narrowed down 16 candidate genes to three genes (*PGAP3*, *GSDMB*, and *GSDMA*).

We attempted to identify functional SNPs using colocalization and conditional eQTL analyses. rs2517954 for *PGAP3* and rs11657449 for *GSDMB* were identified by both colocalization analysis and conditional eQTL analysis, though the posterior probability of colocalization was not high. The probable reason is that the signals of genetic association are not strong due to sample size, and thus, eQTL signals drive the colocalization findings in SARP. Colocalization analysis through conditional eQTL analysis (Table E12) further indicates that the colocalization analysis based on the Bayesian approach does not show strong evidence for colocalization.

Previous studies have shown inconsistent relationship between gene expression in this region and asthma susceptibility.<sup>62</sup> The mRNA levels of *ORMDL3* in lymphoblastoid cell lines have not been significantly different in children with or without asthma.<sup>1</sup> An immunohistochemistry study has found that *GSDMB* protein levels are significantly higher in subjects with asthma than controls.<sup>89</sup> In this study, higher mRNA levels of *GSDMB* were correlated with asthma and asthma exacerbations, though the correlation was not strong and not always consistently significant. Although our findings are based on relevant tissues (BEC) in relevant subjects (healthy controls, non-severe and severe asthma), subjects involved in this study are all adults



(age $\geq$ 12 years old). Typical of adult asthma cohorts, the SARP cohort consists of those with early onset of asthma and those with older age onset.<sup>63,67</sup> Since asthma is often an early-onset disease, expression or eQTL analyses in children would be interesting but, of course, research bronchoscopies are not performed in children. In this study, gene expression correlation and eQTL analyses were performed in all SARP subjects with mixed races to increase sample size and power. Although gene expression is less influenced by population stratification than genetic association, the findings may still be biased due to different allele frequencies and LD structures in different ethnic groups. Correlation analysis of gene expression (*PGAP3*, *GSDMB*, and *GSDMA*) and asthma phenotypes (Table IV) and eQTL analysis of top five eQTL SNPs for these three genes (Table E4) were also performed in SARP non-Hispanic Whites (Table E24 and Table E25). The findings of gene expression correlation and eQTL analyses were similar between non-Hispanic Whites and all subjects with mixed races. In summary, the association of SNPs in *GSDMB*, the expression levels of *GSDMB*, and asthma phenotypes make *GSDMB* a strong candidate for severe asthma.

The function of *PGAP3*, *GSDMB*, or *GSDMA* is not totally understood. *PGAP3* may have a role in controlling autoimmunity and Th1/Th2 balance.<sup>90</sup> *GSDMA* may regulate or be regulated by TGF- $\beta$ 1 and mediate immune defense by inducing pyroptosis.<sup>91</sup> *GSDMB* may regulate apoptosis of epithelial cells and upregulate expression of airway remodeling genes, chemokines, and heat-shock proteins.<sup>89,91</sup> In this study, the expression levels of *GSDMB* are positively correlated with MHC class I molecules (*HLA-A/-B/-C/-F*), type I interferon (*STAT1*, *STAT2*, and *IRF9*) and type II interferon pathway genes (*IFN- $\gamma$*  and *STAT1*), and Th1 pathway genes (*IFN- $\gamma$* , *STAT1*, *IL18R1*, and *IL18BP*). All these biological pathways are related to antiviral process, indicating that virus

infection and expression of antiviral pathway genes may lead to severe asthma and asthma exacerbations. rs7216389 in *GSDMB* has been associated with human rhinovirus (HRV) induced wheezing illnesses in children and increased expression of *GSDMB* and *ORMDL3* in HRV-stimulated peripheral-blood mononuclear cells, which further indicates the potential interaction of *GSDMB* and virus infection in asthma pathogenesis.<sup>92</sup> In a previous gene expression analysis in human nasal epithelial cells, *GSDMB* expression can be induced by IFN- $\alpha$  stimulation.<sup>93</sup> In this study, two SNPs (rs1031458 and rs3902920) in the promoter region of *GSDMB* are colocalized with IRF binding sites and associated with *GSDMB* expression, atopic early onset asthma, asthma severity, and longitudinal asthma exacerbations, making them potential functional SNPs.

One main disadvantage of this study is the relatively small sample size. In genetic association, eQTL, and gene expression correlation analyses, nominal p-values of 0.05 in addition to adjusted p-values have been used. Furthermore, the replication results in several datasets are not always consistently significant. Thus, it requires careful interpretation as for significance and replication. One main advantage of this study is that multi-level evidence point to the same gene (*GSDMB*).

In conclusion, we identified that three independent signals (*PGAP3*, *GSDMB*, and *GSDMA*) were associated with asthma susceptibility and *GSDMB* was also associated with asthma severity, asthma exacerbations, and antiviral pathways. Future candidate gene studies in large, multi-ethnic, or children with asthma and functional experiments may further reveal functional SNPs/genes for asthma including rare variants in this important region.

**Figure Legends**

**FIG 1.** Flow chart of genetic analyses in chr17q12-21.2 region

**FIG 2.** Risk allele frequency of rs1031458 (A) and rs3902920 (B) in *GSDMB* stratified by age onset of asthma and atopic status. Chi-square test was performed by comparing each asthma group with general North-Western European controls shown in red line (gnomAD V2.1.1; <https://gnomad.broadinstitute.org/>).

544 **ACKNOWLEDGMENTS**

545 We acknowledge all investigators, staff, and participants in the SARP studies.

**REFERENCES**

1. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. *Nature*. 2007;448(7152):470-3.
2. Anantharaman R, Andiappan AK, Nilkanth PP, Suri BK, Wang de Y, Chew FT. Genome-wide association study identifies PERLD1 as asthma candidate gene. *BMC Med Genet*. 2011;12:170.
3. Halapi E, Gudbjartsson DF, Jonsdottir GM, Bjornsdottir US, Thorleifsson G, Helgadottir H, et al. A sequence variant on 17q21 is associated with age at onset and severity of asthma. *Eur J Hum Genet*. 2010;18(8):902-8.
4. Nicodemus-Johnson J, Myers RA, Sakabe NJ, Sobreira DR, Hogarth DK, Naureckas ET, et al. DNA methylation in lung cells is associated with asthma endotypes and genetic risk. *JCI Insight*. 2016;1(20):e90151.
5. Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmuller J, Ang W, et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat Genet*. 2018;50(1):42-53.
6. Shrine N, Portelli MA, John C, Soler Artigas M, Bennett N, Hall R, et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. *Lancet Respir Med*. 2019;7(1):20-34.
7. Daya M, Rafaels N, Brunetti TM, Chavan S, Levin AM, Shetty A, et al. Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. *Nat Commun*. 2019;10(1):880.

8. Yan Q, Brehm J, Pino-Yanes M, Forno E, Lin J, Oh SS, et al. A meta-analysis of genome-wide association studies of asthma in Puerto Ricans. *Eur Respir J*. 2017;49(5).
9. Ferreira MA, Matheson MC, Tang CS, Granell R, Ang W, Hui J, et al. Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype. *J Allergy Clin Immunol*. 2014;133(6):1564-71.
10. Pickrell JK, Berisa T, Liu JZ, Segurel L, Tung JY, Hinds DA. Detection and interpretation of shared genetic influences on 42 human traits. *Nat Genet*. 2016;48(7):709-17.
11. Schmiedel BJ, Seumois G, Samaniego-Castruita D, Cayford J, Schulten V, Chavez L, et al. 17q21 asthma-risk variants switch CTCF binding and regulate IL-2 production by T cells. *Nat Commun*. 2016;7:13426.
12. Pividori M, Schoettler N, Nicolae DL, Ober C, Im HK. Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies. *Lancet Respir Med*. 2019;7(6):509-22.
13. Ferreira MAR, Mathur R, Vonk JM, Sz wajda A, Brumpton B, Granell R, et al. Genetic Architectures of Childhood- and Adult-Onset Asthma Are Partly Distinct. *Am J Hum Genet*. 2019;104(4):665-84.
14. Bonnelykke K, Sleiman P, Nielsen K, Kreiner-Moller E, Mercader JM, Belgrave D, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. *Nat Genet*. 2014;46(1):51-5.
15. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med*. 2010;363(13):1211-21.

- 591 16. Almoguera B, Vazquez L, Mentch F, Connolly J, Pacheco JA, Sundaresan AS, et al.  
592 Identification of Four Novel Loci in Asthma in European American and African  
593 American Populations. *Am J Respir Crit Care Med*. 2017;195(4):456-63.
- 594 17. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, et al.  
595 Meta-analysis of genome-wide association studies of asthma in ethnically diverse North  
596 American populations. *Nat Genet*. 2011;43(9):887-92.
- 597 18. Morrison FS, Locke JM, Wood AR, Tuke M, Pasko D, Murray A, et al. The splice site  
598 variant rs11078928 may be associated with a genotype-dependent alteration in expression  
599 of GSDMB transcripts. *BMC Genomics*. 2013;14:627.
- 600 19. Nieuwenhuis MA, Siedlinski M, van den Berge M, Granell R, Li X, Niens M, et al.  
601 Combining genomewide association study and lung eQTL analysis provides evidence for  
602 novel genes associated with asthma. *Allergy*. 2016;71(12):1712-20.
- 603 20. Zhu Z, Lee PH, Chaffin MD, Chung W, Loh PR, Lu Q, et al. A genome-wide cross-trait  
604 analysis from UK Biobank highlights the shared genetic architecture of asthma and  
605 allergic diseases. *Nat Genet*. 2018;50(6):857-64.
- 606 21. Loss GJ, Depner M, Hose AJ, Genuneit J, Karvonen AM, Hyvarinen A, et al. The Early  
607 Development of Wheeze. Environmental Determinants and Genetic Susceptibility at  
608 17q21. *Am J Respir Crit Care Med*. 2016;193(8):889-97.
- 609 22. Acevedo N, Reinius LE, Greco D, Gref A, Orsmark-Pietras C, Persson H, et al. Risk of  
610 childhood asthma is associated with CpG-site polymorphisms, regional DNA methylation  
611 and mRNA levels at the GSDMB/ORMDL3 locus. *Hum Mol Genet*. 2015;24(3):875-90.

23. Galanter J, Choudhry S, Eng C, Nazario S, Rodriguez-Santana JR, Casal J, et al. ORMDL3 gene is associated with asthma in three ethnically diverse populations. *Am J Respir Crit Care Med*. 2008;177(11):1194-200.
24. Wan YI, Shrine NR, Soler Artigas M, Wain LV, Blakey JD, Moffatt MF, et al. Genome-wide association study to identify genetic determinants of severe asthma. *Thorax*. 2012;67(9):762-8.
25. Ferreira MA, McRae AF, Medland SE, Nyholt DR, Gordon SD, Wright MJ, et al. Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia. *Eur J Hum Genet*. 2011;19(4):458-64.
26. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science*. 2015;348(6235):648-60.
27. Marenholz I, Esparza-Gordillo J, Ruschendorf F, Bauerfeind A, Strachan DP, Spycher BD, et al. Meta-analysis identifies seven susceptibility loci involved in the atopic march. *Nat Commun*. 2015;6:8804.
28. Waage J, Standl M, Curtin JA, Jessen LE, Thorsen J, Tian C, et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. *Nat Genet*. 2018;50(8):1072-80.
29. Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nat Genet*. 2017;49(12):1752-7.
30. Hinds DA, McMahon G, Kiefer AK, Do CB, Eriksson N, Evans DM, et al. A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. *Nat Genet*. 2013;45(8):907-11.



31. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. *Nat Commun.* 2017;8:16021.
32. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. *Nat Genet.* 2017;49(2):256-61.
33. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet.* 2015;47(9):979-86.
34. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kempainen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nat Genet.* 2013;45(11):1353-60.
35. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature.* 2012;491(7422):119-24.
36. Morris DL, Sheng Y, Zhang Y, Wang YF, Zhu Z, Tomblinson P, et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. *Nat Genet.* 2016;48(8):940-6.
37. Bentham J, Morris DL, Graham DSC, Pinder CL, Tomblinson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat Genet.* 2015;47(12):1457-64.

- 658 38. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis  
659 associated with HLA, IL12A, and IL12RB2 variants. *N Engl J Med.* 2009;360(24):2544-  
660 55.
- 661 39. Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, et al. Genome-wide  
662 association studies identify PRKCB as a novel genetic susceptibility locus for primary  
663 biliary cholangitis in the Japanese population. *Hum Mol Genet.* 2017;26(3):650-9.
- 664 40. Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, et al. International  
665 genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and  
666 targetable pathogenic pathways. *Nat Commun.* 2015;6:8019.
- 667 41. Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, et al.  
668 Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci  
669 for primary biliary cirrhosis in the Japanese population. *Am J Hum Genet.*  
670 2012;91(4):721-8.
- 671 42. Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, et al. Genome-wide meta-analyses  
672 identify three loci associated with primary biliary cirrhosis. *Nat Genet.* 2010;42(8):658-  
673 60.
- 674 43. Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, Castellvi I, et al. A  
675 systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new  
676 shared susceptibility loci. *Hum Mol Genet.* 2013;22(19):4021-9.
- 677 44. Qiu F, Tang R, Zuo X, Shi X, Wei Y, Zheng X, et al. A genome-wide association study  
678 identifies six novel risk loci for primary biliary cholangitis. *Nat Commun.* 2017;8:14828.

45. Waage J, Standl M, Curtin JA, Jessen LE, Thorsen J, Tian C, et al. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. *Nat Genet.* 2018;50(8):1072-80.
46. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet.* 2016;48(5):510-8.
47. Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. *Nat Med.* 2015;21(9):1018-27.
48. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. *Nat Genet.* 2012;44(12):1336-40.
49. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet.* 2010;42(6):508-14.
50. Plagnol V, Howson JM, Smyth DJ, Walker N, Hafler JP, Wallace C, et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. *PLoS Genet.* 2011;7(8):e1002216.
51. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet.* 2011;43(3):246-52.

- 700 52. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al.  
701 Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease  
702 susceptibility loci. *Nat Genet.* 2010;42(12):1118-25.
- 703 53. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide  
704 association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat*  
705 *Genet.* 2008;40(8):955-62.
- 706 54. Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK, et al. High-density genotyping  
707 of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk  
708 loci. *Ann Rheum Dis.* 2015;74(3):e13.
- 709 55. Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. Dense fine-  
710 mapping study identifies new susceptibility loci for primary biliary cirrhosis. *Nat Genet.*  
711 2012;44(10):1137-41.
- 712 56. Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et  
713 al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of  
714 causal variants with lymphoid gene enhancers. *Nat Genet.* 2015;47(4):381-6.
- 715 57. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, et al. Genome-  
716 wide association identifies multiple ulcerative colitis susceptibility loci. *Nat Genet.*  
717 2010;42(4):332-7.
- 718 58. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-  
719 wide association study and meta-analysis find that over 40 loci affect risk of type 1  
720 diabetes. *Nat Genet.* 2009;41(6):703-7.

59. Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. *Am J Hum Genet.* 2014;94(1):47-61.
60. Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, et al. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. *Ann Rheum Dis.* 2017;76(6):1150-8.
61. Li X, Ampleford EJ, Howard TD, Moore WC, Torgerson DG, Li H, et al. Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases. *J Allergy Clin Immunol.* 2012;130(4):861-8 e7.
62. Stein MM, Thompson EE, Schoettler N, Helling BA, Magnaye KM, Stanhope C, et al. A decade of research on the 17q12-21 asthma locus: Piecing together the puzzle. *J Allergy Clin Immunol.* 2018;142(3):749-64 e3.
63. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol.* 2007;119(2):405-13.
64. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med.* 2010;181(4):315-23.
65. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. *Am J Respir Crit Care Med.* 2012;185(4):356-62.

- 743 66. Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, et al.  
744 Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent  
745 Exacerbations. *Am J Respir Crit Care Med*. 2017;195(3):302-13.
- 746 67. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al.  
747 Baseline Features of the Severe Asthma Research Program (SARP III) Cohort:  
748 Differences with Age. *J Allergy Clin Immunol Pract*. 2018;6(2):545-54 e4.
- 749 68. Wu W, Bang S, Bleecker ER, Castro M, Denlinger L, Erzurum SC, et al. Multiview  
750 Cluster Analysis Identifies Variable Corticosteroid Response Phenotypes in Severe  
751 Asthma. *Am J Respir Crit Care Med*. 2019;199(11):1358-67.
- 752 69. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a  
753 tool set for whole-genome association and population-based linkage analyses. *Am J Hum*  
754 *Genet*. 2007;81(3):559-75.
- 755 70. Li X, Ortega VE, Ampleford EJ, Graham Barr R, Christenson SA, Cooper CB, et al.  
756 Genome-wide association study of lung function and clinical implication in heavy  
757 smokers. *BMC Med Genet*. 2018;19(1):134.
- 758 71. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation  
759 genotype imputation service and methods. *Nat Genet*. 2016;48(10):1284-7.
- 760 72. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast  
761 universal RNA-seq aligner. *Bioinformatics*. 2013;29(1):15-21.
- 762 73. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for  
763 RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.

74. Li X, Hastie AT, Hawkins GA, Moore WC, Ampleford EJ, Milosevic J, et al. eQTL of bronchial epithelial cells and bronchial alveolar lavage deciphers GWAS-identified asthma genes. *Allergy*. 2015;70(10):1309-18.
75. Li X, Hawkins GA, Moore WC, Hastie AT, Ampleford EJ, Milosevic J, et al. Expression of asthma susceptibility genes in bronchial epithelial cells and bronchial alveolar lavage in the Severe Asthma Research Program (SARP) cohort. *J Asthma*. 2016;53(8):775-82.
76. Modena BD, Tedrow JR, Milosevic J, Bleecker ER, Meyers DA, Wu W, et al. Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. *Am J Respir Crit Care Med*. 2014;190(12):1363-72.
77. Modena BD, Bleecker ER, Busse WW, Erzurum SC, Gaston BM, Jarjour NN, et al. Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. *Am J Respir Crit Care Med*. 2017;195(11):1449-63.
78. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res*. 2019;47(D1):D1005-D12.
79. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. *Genome Res*. 2002;12(6):996-1006.
80. Li MX, Yeung JM, Cherny SS, Sham PC. Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. *Hum Genet*. 2012;131(5):747-56.
81. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005;21(2):263-5.

82. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet*. 2014;10(5):e1004383.
83. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. *Nucleic Acids Res*. 2018;46(D1):D649-D55.
84. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* 2012; 489: 57-74.
85. Hao K, Bossé Y, Nickle DC, Paré PD, Postma DS, Laviolette M, et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. *PLoS Genet*. 2012;8(11):e1003029.
86. Ober C, McKennan CG, Magnaye KM, Altman MC, Washington C 3rd, Stanhope C, et al. Expression quantitative trait locus fine mapping of the 17q12-21 asthma locus in African American children: a genetic association and gene expression study. *Lancet Respir Med*. 2020;8(5):482-492.
87. Sandra JH, Greg LH, Mark H, Paul NR. Flow Cytometric Characterization of Cell Populations in Bronchoalveolar Lavage and Bronchial Brushings From Patients With Chronic Obstructive Pulmonary Disease. *Cytometry B Clin Cytom*. 2004;61(1):27-34.
88. Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T, et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards Database (Oxford). 2017.
89. Das S, Miller M, Beppu AK, Mueller J, McGeough MD, Vuong C, et al. GSDMB induces an asthma phenotype characterized by increased airway responsiveness and remodeling without lung inflammation. *Proc Natl Acad Sci U S A*. 2016;113(46):13132-7.



- 809 90. Wang Y, Murakami Y, Yasui T, Wakana S, Kikutani H, Kinoshita T, et al. Significance  
810 of glycosylphosphatidylinositol-anchored protein enrichment in lipid rafts for the control  
811 of autoimmunity. *J Biol Chem*. 2013;288(35):25490-9.
- 812 91. Das S, Miller M, Broide DH. Chromosome 17q21 Genes ORMDL3 and GSDMB in  
813 Asthma and Immune Diseases. *Adv Immunol*. 2017;135:1-52.
- 814 92. Caliskan M, Bochkov YA, Kreiner-Moller E, Bonnelykke K, Stein MM, Du G, et al.  
815 Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med*.  
816 2013;368(15):1398-407.
- 817 93. Giovannini-Chami L, Marcet B, Moreilhon C, et al. Distinct epithelial gene expression  
818 phenotypes in childhood respiratory allergy. *Eur Respir J* 2012; 39: 1197-1205.

819 **TABLE I.** Demographics (mean±SDs) of subjects in SARP

	RNAseq (BEC) Longitudinal		Microarray (BEC) Cross-sectional		WGS†				
	All	WGS	All	GWAS	Severe Asthma	Non-severe Asthma	Longitudinal Exacerbations	Non-Hispanic White	African American
n	156	114	155	120	426	531	273	1,016	622
Age	41±13	41±13	37±13	36±13	46±15	37±15	47±16	39±17	29±17
Female, n (%)	99 (63)	74 (65)	101 (65)	80 (67)	269 (63)	353 (66)	176 (64)	656 (65)	369 (59)
BMI	30±8.1	30±8.7	30±6.8	30±7.0	31±7.7	28±7.6	31±7.9	29±7.9	30±11
Race (Non-Hispanic White/African American/Other*), %	67/24/9	65/26/9	62/29/9	60/29/11	100/0/0	100/0/0	100/0/0	100/0/0	0/100/0
Baseline % predicted FEV <sub>1</sub>	82±21	76±20	76±22	76±23	66±22	84±17	73±21	77±21	78±20
Baseline FEV <sub>1</sub> /FVC	0.73±0.10	0.70±0.10	0.72±0.12	0.71±0.13	0.66±0.13	0.75±0.09	0.69±0.11	0.72±0.12	0.72±0.11
Asthma status (Control/Non-severe/Severe), n	42/49/65	0/49/65	27/78/50	19/60/41	0/0/426	0/531/0	0/111/162	0/564/451	0/270/252
Age Onset of Asthma<18 yrs, n (%)	77 (68)	77 (68)	88 (71)	69 (68)	238 (56)	348 (66)	164 (60)	645 (64)	394 (75)

820 Note: BEC: bronchial epithelial cell brushing; Microarray: Agilent Whole Human Genome Microarray 4x44K v2; WGS: whole-  
821 genome sequence; GWAS: genome-wide association study.

822 \*Other races include Hispanic, Asian, American Indian, and mixed.

823 †1,016 non-Hispanic Whites and 622 African Americans in SARP longitudinal and cross-sectional cohorts with WGS were used for  
824 LD calculation; Among 1,016 non-Hispanic Whites, 957 adults (age ≥ 12 yrs) (426 with severe asthma vs. 531 with non-severe  
825 asthma) were included in the genetic association analysis of asthma severity; 273 adults in the longitudinal cohort were included in the  
826 genetic association analysis of longitudinal asthma exacerbations.

827 **TABLE II.** Genetic association and eQTL results of 48 GWAS-identified SNPs associated with expression levels of *PGAP3*, *GSDMB*,  
828 or *GSDMA* in the longitudinal cohort

SNP	Position (hg38)	SNP Type	Gene	Allele†	Associated Trait**	LD†† (NHW)	LD†† (AA)	Asthma Severity***			Number of Exacerbations in 3 years†††		eQTL of SARP3 in BEC (n=114)			eQTL of GTEx database Lung Tissue (n=383)
								Effect Allele	OR	P	β	P	PGAP3 β (P)	GSDMB β (P)	GSDMA β (P)	
rs2941504*	39674647	synonymous	<i>PGAP3</i>	A/G	Asthma <sup>2</sup> ; eQTL for <i>PGAP3</i> <sup>3</sup>	1	1	A	1.05	0.64	0.97	0.011	0.77 (5E-9)	0.30 (0.03)	-0.32 (0.02)	A ~ <i>PGAP3</i> ↑ (2E-10); <i>ORMDL3</i> ↑ (1E-7); <i>GSDMA</i> ↓ (4E-6)
rs2517955*	39687428	intronic	<i>PGAP3</i>	C/T	eQTL for <i>ORMDL3</i>			C	1.10	0.35	1.05	0.0034	0.56 (5E-6)	0.28 (0.03)	-0.11 (0.4)	C ~ <i>PGAP3</i> ↑ (1E-12); <i>ORMDL3</i> ↑ (2E-6)
rs2952156*†	39720582	intronic	<i>ERBB2</i>	A/G	Asthma <sup>5</sup>	2	2	A	1.06	0.56	0.99	0.0081	0.76 (4E-8)	0.30 (0.04)	-0.33 (0.02)	A ~ <i>PGAP3</i> ↑ (4E-10); <i>ORMDL3</i> ↑ (4E-9); <i>GSDMA</i> ↓ (7E-6); <i>GSDMB</i> ↑ (2E-5)
rs4252665†	39729130	intronic	<i>ERBB2</i>	T/C	SLE <sup>31</sup>			T	0.69	0.15	-0.40	0.69	-0.02 (1.0)	0.04 (0.9)	-0.28 (0.5)	NS
rs2941522†	39754115	intergenic	<i>GRB7</i> <i>-IKZF3</i>	T/C	Asthma <sup>6</sup>			T	1.24	0.028	0.84	0.019	0.45 (8E-4)	0.33 (0.02)	-0.54 (6E-5)	T ~ <i>GSDMB</i> ↑ (3E-15); <i>ORMDL3</i> ↑ (4E-15); <i>GSDMA</i> ↓ (1E-6); <i>PGAP3</i> ↑ (1E-6)
rs12946510†	39756124	intergenic	<i>GRB7</i> <i>-IKZF3</i>	T/C	UC <sup>32,33</sup> ; CD <sup>32,33</sup> ; MS <sup>3</sup> ; IBD <sup>32,33,35</sup>			T	0.86	0.12	-0.72	0.046	-0.43 (0.002)	-0.43 (0.002)	0.44 (0.002)	T ~ <i>GSDMB</i> ↓ (2E-9); <i>ORMDL3</i> ↓ (9E-9); <i>GSDMA</i> ↑ (1E-6)
rs2941509†	39764941	3' UTR	<i>IKZF3</i>	A/G	SLE <sup>36,37</sup>			A	0.81	0.44	0.46	0.65	-0.08 (0.7)	0.04 (0.9)	0.02 (0.9)	A ~ <i>GSDMB</i> ↓ (3E-5)
rs907092*†	39766006	synonymous	<i>IKZF3</i>	G/A A/G	Asthma <sup>38</sup> ; PBCh <sup>38</sup>			G	1.24	0.027	0.66	0.069	0.47 (8E-4)	0.50 (4E-4)	-0.43 (0.003)	G ~ <i>GSDMB</i> ↑ (2E-9); <i>ORMDL3</i> ↑ (5E-9); <i>GSDMA</i> ↓ (2E-7)
rs10445308†	39781794	intronic	<i>IKZF3</i>	C/T	Atopy <sup>27</sup>			C	1.23	0.033	0.76	0.034	0.47 (7E-4)	0.51 (2E-4)	-0.45 (1E-3)	C ~ <i>GSDMB</i> ↑ (7E-10); <i>ORMDL3</i> ↑ (3E-9); <i>GSDMA</i> ↓ (3E-8)
rs12450323†	39816455	intronic	<i>IKZF3</i>	T/G	Asthma <sup>9</sup>			T	1.15	0.24	0.96	0.023	0.63 (2E-4)	0.43 (0.01)	0.13 (0.4)	T ~ <i>ORMDL3</i> ↑ (1E-5); <i>GSDMB</i> ↑ (2E-5); <i>PGAP3</i> ↑ (2E-5)
rs9303277*†	39820216	intronic	<i>IKZF3</i>	T/C	PBCh <sup>38</sup> ; SS <sup>3</sup> ; SLE <sup>3</sup>			T	0.79	0.017	-0.84	0.017	-0.48 (4E-4)	-0.40 (0.004)	0.49 (3E-4)	T ~ <i>GSDMB</i> ↓ (7E-15); <i>ORMDL3</i> ↓ (6E-14); <i>GSDMA</i> ↑ (2E-7); <i>PGAP3</i> ↓ (7E-6)
rs143123127†	39850937	intronic	<i>IKZF3</i>	A/G	SLE <sup>37</sup>			A	0.80	0.43	-0.38	0.73	-0.02 (1.0)	0.30 (0.5)	-0.77 (0.06)	NA
rs9635726†	39863888	intronic	<i>IKZF3</i>	C/T	PBCh			C	0.88	0.27	-1.14	0.0078	-0.63 (1E-4)	-0.47 (0.005)	-0.07 (0.7)	C ~ <i>GSDMB</i> ↓ (1E-5); <i>ORMDL3</i> ↓ (2E-5); <i>PGAP3</i> ↓ (2E-5)
rs4795397†	39867492	intergenic	<i>IKZF3</i> <i>-ZBP2</i>	A/G (G/A)	Asthma <sup>8</sup> ; IBD <sup>31</sup>			A	1.17	0.027	0.81	0.022	0.40 (0.003)	0.52 (1E-4)	-0.42 (0.002)	A ~ <i>ORMDL3</i> ↑ (4E-9); <i>GSDMA</i> ↓ (2E-8); <i>GSDMB</i> ↑ (7E-8)
rs11655198†	39869916	intronic	<i>ZBP2</i>	(C/T)	Asthma <sup>10</sup>			C	1.29	0.0097	0.82	0.019	0.40 (0.003)	0.44 (0.001)	-0.30 (0.03)	C ~ <i>GSDMB</i> ↑ (6E-15); <i>ORMDL3</i> ↑ (8E-12); <i>GSDMA</i> ↓ (8E-7); <i>PGAP3</i> ↑ (3E-6)
rs12936231*	39872867	intronic	<i>ZBP2</i>	(C/G)	<i>ORMDL3</i> promoter <sup>41</sup>			C	1.29	0.0089	0.87	0.013	0.40 (0.004)	0.42 (0.002)	-0.37 (0.008)	C ~ <i>GSDMB</i> ↑ (5E-15); <i>ORMDL3</i> ↑ (1E-14); <i>GSDMA</i> ↓ (1E-7); <i>PGAP3</i> ↑ (8E-6)
rs59716545†	39875604	intronic	<i>ZBP2</i>	(G/T)	RA <sup>5</sup>			G	0.82	0.042	-0.89	0.012	-0.38 (0.005)	-0.52 (1E-4)	0.31 (0.02)	NA
rs12939457†	39875935	intronic	<i>ZBP2</i>	T/C	Allergic rhinitis <sup>39</sup>			T	1.21	0.054	0.90	0.011	0.44 (0.002)	0.50 (3E-4)	-0.40 (0.004)	NA
rs35736272†	39876427	intronic	<i>ZBP2</i>	(C/T)	AD <sup>6</sup>			C	0.81	0.033	-0.89	0.012	-0.40 (0.003)	-0.53 (6E-5)	0.35 (0.01)	C ~ <i>ORMDL3</i> ↓ (7E-10); <i>GSDMB</i> ↓ (3E-9); <i>GSDMA</i> ↑ (4E-9);
rs12232497†	39883866	intergenic	<i>ZBP2</i> <i>-GSDMB</i>	C/T	AD <sup>7</sup>			C	0.81	0.033	-0.89	0.012	-0.40 (0.003)	-0.53 (6E-5)	0.35 (0.01)	C ~ <i>ORMDL3</i> ↓ (7E-10); <i>GSDMA</i> ↑ (3E-9); <i>GSDMB</i> ↓ (3E-9)
rs2872507†	39884510	intergenic	<i>ZBP2</i> <i>-GSDMB</i>	A/G	RA <sup>8</sup> ; T1D <sup>30</sup> ; UC <sup>41</sup> ; CD <sup>32,33</sup>			A	0.81	0.035	-0.89	0.012	-0.42 (0.002)	-0.51 (2E-4)	0.35 (0.01)	A ~ <i>ORMDL3</i> ↓ (3E-10); <i>GSDMB</i> ↓ (5E-10); <i>GSDMA</i> ↑ (2E-9)

rs12936409†	39887396	intergenic	<i>ZBP2</i> <i>-GSDMB</i>	T/C	RA <sup>8,5</sup>	3	4	T	0.81	0.030	-0.88	0.014	-0.43 (0.002)	-0.52 (1E-4)	0.36 (0.009)	T ~ ORM3L3† (8E-10); GSDMA† (4E-9); GSDMB† (9E-9)
rs8067378†	39895095	intergenic	<i>ZBP2</i> <i>-GSDMB</i>	G/A	PBC1 <sup>55</sup>			G	0.76	0.0054	-0.88	0.011	-0.43 (0.002)	-0.42 (0.003)	0.36 (0.01)	G ~ GSDMB† (5E-15); ORM3L3† (1E-14); GSDMA† (1E-7); PGAP3† (8E-6)
rs12453507†	39896954	intergenic	<i>ZBP2</i> <i>-GSDMB</i>	(G/C)	TID <sup>56</sup>			G	0.76	0.0050	-0.78	0.024	-0.36 (0.007)	-0.43 (1E-3)	0.29 (0.03)	G ~ GSDMB† (2E-15); ORM3L3† (2E-12); GSDMA† (2E-8); PGAP3† (1E-6)
rs8069176*†	39900944	intergenic	<i>ZBP2</i> <i>-GSDMB</i>	G/A	Asthma <sup>5</sup>			G	1.26	0.020	0.86	0.015	0.39 (0.003)	0.57 (9E-6)	-0.33 (0.01)	G ~ ORM3L3† (6E-11); GSDMA† (1E-10); GSDMB† (2E-10)
rs4795399†	39905186	intronic	<i>GSDMB</i>	T/C	Asthma <sup>12,13</sup>			T	1.26	0.019	0.88	0.013	0.35 (0.007)	0.55 (2E-5)	-0.31 (0.02)	T ~ ORM3L3† (1E-10); GSDMA† (2E-10); GSDMB† (7E-10)
rs2305480*†	39905943	missense	<i>GSDMB</i>	G/A A/G	Asthma <sup>15</sup> RA <sup>5</sup> ; UC <sup>57</sup>			G	1.27	0.015	0.93	0.0086	0.35 (0.007)	0.55 (3E-5)	-0.31 (0.02)	G ~ ORM3L3† (1E-10); GSDMA† (2E-10); GSDMB† (2E-9)
rs2305479†	39905964	missense	<i>GSDMB</i>	(C/T)	Asthma <sup>5</sup>			C	1.34	0.0029	0.85	0.014	0.33 (0.01)	0.46 (3E-4)	-0.26 (0.05)	C ~ GSDMB† (6E-15); ORM3L3† (4E-15); GSDMA† (1E-7); PGAP3† (5E-6)
rs62067034†	39907485	intronic	<i>GSDMB</i>	(C/T)	Asthma <sup>16</sup>			C	1.34	0.0029	0.85	0.014	0.33 (0.01)	0.46 (3E-4)	-0.26 (0.05)	C ~ GSDMB† (2E-15); ORM3L3† (1E-12); GSDMA† (1E-7); PGAP3† (7E-6)
rs11078927*†	39908152	intronic	<i>GSDMB</i>	C/T	Asthma <sup>17</sup>			C	1.26	0.018	0.95	0.0073	0.37 (0.005)	0.56 (2E-5)	-0.35 (0.009)	C ~ ORM3L3† (1E-10); GSDMA† (3E-10); GSDMB† (9E-10)
rs11078928*	39908216	splice receptor	<i>GSDMB</i>	T/C	eQTL for GSDMB <sup>18</sup>			T	1.26	0.018	0.95	0.0073	0.37 (0.005)	0.56 (2E-5)	-0.35 (0.009)	T ~ ORM3L3† (8E-11); GSDMA† (4E-10); GSDMB† (8E-10)
rs117097909†	39908718	intronic	<i>GSDMB</i>	A/G	Asthma <sup>13</sup>	4	5	A	1.04	0.860	-0.04	0.95	0.27 (0.37)	0.52 (0.09)	0.21 (0.49)	NA
rs2290400*†	39909987	intronic	<i>GSDMB</i>	T/C (C/T)	Asthma <sup>19</sup> TID <sup>58</sup>			T	1.32	0.0044	0.84	0.016	0.40 (0.003)	0.41 (0.003)	-0.35 (0.01)	T ~ GSDMB† (8E-16); ORM3L3† (7E-15); GSDMA† (1E-8); PGAP3† (3E-6)
rs4795400†	39910767	intronic	<i>GSDMB</i>	(C/T)	Allergy <sup>10</sup>			C	1.27	0.015	0.91	0.0093	0.35 (0.007)	0.55 (3E-5)	-0.31 (0.02)	C ~ ORM3L3† (2E-10); GSDMB† (3E-10); GSDMA† (5E-10)
rs869402†	39911790	intronic	<i>GSDMB</i>	(C/T)	Asthma <sup>20</sup>			C	1.33	0.0039	0.81	0.019	0.31 (0.01)	0.41 (1E-3)	-0.24 (0.06)	C ~ GSDMB† (1E-15); ORM3L3† (2E-12); GSDMA† (2E-7); PGAP3† (3E-6)
rs921650†	39912823	intronic	<i>GSDMB</i>	A/G	Allergy <sup>29</sup>			A	1.32	0.0045	0.80	0.021	0.33 (0.009)	0.47 (2E-4)	-0.27 (0.03)	A ~ GSDMB† (1E-15); ORM3L3† (8E-13); GSDMA† (2E-7); PGAP3† (3E-6)
rs7216389*†	39913696	intronic	<i>GSDMB</i>	T/C	Asthma <sup>1</sup>			T	1.32	0.0045	0.80	0.021	0.33 (0.009)	0.47 (2E-4)	-0.27 (0.03)	T ~ GSDMB† (1E-15); ORM3L3† (8E-13); GSDMA† (2E-7); PGAP3† (3E-6)
rs9303280†	39917778	intronic	<i>GSDMB</i>	C/T	Allergy <sup>30</sup>			C	1.32	0.0049	0.77	0.028	0.37 (0.004)	0.49 (1E-4)	-0.33 (0.01)	C ~ GSDMB† (3E-15); ORM3L3† (2E-12); GSDMA† (3E-9); PGAP3† (9E-6)
rs4065275*	39924612	intronic	<i>ORMDL3</i>	G/A	ORMDL3 promoter <sup>11</sup>			G	1.31	0.0064	0.82	0.020	0.31 (0.02)	0.36 (0.008)	-0.29 (0.04)	G ~ GSDMB† (1E-13); ORM3L3† (1E-13); GSDMA† (6E-11)
rs8076131*	39924659	intronic	<i>ORMDL3</i>	A/G	Early wheeze <sup>21</sup>			A	1.25	0.022	0.85	0.015	0.36 (0.007)	0.47 (3E-4)	-0.37 (0.006)	A ~ GSDMA† (1E-11); ORM3L3† (7E-11); GSDMB† (1E-9)
rs12603332*	39926554	5' UTR	<i>ORMDL3</i>	C/T	eQTL and meQTL for ORMDL3/GSDMB <sup>22,23</sup>	4	5	C	1.31	0.0060	0.83	0.018	0.29 (0.03)	0.40 (0.003)	-0.44 (9E-4)	C ~ ORM3L3† (2E-14); GSDMB† (2E-13); GSDMA† (6E-12); PGAP3† (2E-5)
rs4794820†	39933091	intronic	<i>ORMDL3</i>	(G/A)	Asthma <sup>2</sup>			G	1.26	0.021	0.94	0.0077	0.28 (0.04)	0.40 (0.002)	-0.38 (0.004)	G ~ GSDMA† (2E-17); ORM3L3† (2E-11); GSDMB† (2E-8)
rs6503525†	39938921	intergenic	<i>ORMDL3</i> <i>-LRRC3C</i>	(C/G)	Asthma <sup>25</sup>	5	6	C	1.23	0.038	0.57	0.12	0.25 (0.06)	0.076 (0.6)	-0.37 (0.005)	C ~ GSDMA† (6E-21); GSDMB† (9E-8); ORM3L3† (2E-5)
rs3902025†	39963001	5' UTR	<i>GSDMA</i>	C/A	SS <sup>59</sup>			C	0.81	0.033	-0.65	0.072	-0.30 (0.02)	-0.23 (0.09)	0.48 (3E-4)	C ~ GSDMA† (2E-21); ORM3L3† (9E-7); GSDMB† (1E-5)
rs3894194*†	39965740	missense	<i>GSDMA</i>	A/G G/A	Asthma <sup>1,15</sup> SS <sup>60</sup>			A	1.14	0.20	0.33	0.35	0.36 (0.006)	0.10 (0.4)	-0.46 (4E-4)	A ~ GSDMA† (1E-21); GSDMB† (4E-9); ORM3L3† (2E-7)
rs7212938†	39966427	missense	<i>GSDMA</i>	G/T	Asthma <sup>6</sup>			G	1.14	0.19	0.28	0.44	0.27 (0.04)	0.14 (0.3)	-0.28 (0.03)	G ~ GSDMA† (3E-18); GSDMB† (1E-7); ORM3L3† (5E-5)
rs3859192*	39972395	intronic	<i>GSDMA</i>	T/C	eQTL for GSDMA <sup>36</sup>			T	0.96	0.68	0.44	0.23	0.41 (0.002)	0.19 (0.2)	-0.42 (0.001)	T ~ GSDMA† (5E-52)
rs11652139†	39992780	intronic	<i>PSMD3</i>	(A/G)	Allergy <sup>29</sup>			A	1.01	0.90	0.47	0.19	0.32 (0.02)	0.29 (0.03)	-0.17 (0.2)	NA

Note: entries with p-value<0.0035 for genetic association analysis of asthma severity or longitudinal asthma exacerbations were labeled in red color. NS: non-significant; NA: non-available.

\*17 SNPs associated with asthma and reported by Stein et al.<sup>62</sup>

†SNPs associated with asthma, allergy, and autoimmune diseases from NHGRI-EBI GWAS catalog ([www.ebi.ac.uk/gwas/](http://www.ebi.ac.uk/gwas/)).<sup>78</sup> incorporated in UCSC genome browser ([genome.ucsc.edu](http://genome.ucsc.edu); accessed on March 1, 2019).<sup>79</sup>

‡Risk allele/Other allele: parenthesis indicates risk allele was not reported in the original study but predicted based on available data.

\*\*AD: autoimmune diseases; CD: Crohn's disease; IBD: inflammatory bowel disease; MS: multiple sclerosis; PBCh: primary biliary cholangitis; PBCi: primary biliary cirrhosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SS: systemic sclerosis; T1D: type I diabetes; UC: ulcerative colitis.

†† LD was estimated with 95% confidence intervals of D' to define LD blocks of 48 SNPs for 1,016 non-Hispanic Whites (NHW) and 622 African Americans (AA) in SARP longitudinal cohort and cross-sectional cohort with WGS using Haploview.<sup>81</sup>

\*\*\*OR and P were odds ratio and p-value for genetic association analysis of asthma severity (426 severe vs. 531 non-severe asthma) in non-Hispanic White in SARP.

†††β and P were correlation coefficient and p-value for genetic association analysis of the number of longitudinal exacerbations due to asthma in 3 years in the longitudinal cohort in 273 asthmatics with longitudinal asthma exacerbations in non-Hispanic White in SARP.

843 **TABLE III.** eQTL results of 26 SNPs significantly associated with expression levels of *PGAP3*, *GSDMB*, or *GSDMA* in the  
 844 longitudinal cohort

SNP	Position (hg38)	Gene	LD* (NHW)	LD* (AA)	SARP3 BEC (n=114)						eQTL of GTEx database Lung Tissue (n=383)†	
					A1	PGAP3		GSDMB		GSDMA		
						β	P	β	P	β		P
rs3751903	39627534	PPP1R1B	1	1	C	0.43	0.002	0.55	1.0E-4	-0.10	0.5	C ~ PGAP3↑ (1E-7)
rs3794712	39635234	PPP1R1B			A	0.48	0.007	0.78	6.5E-6	0.06	0.7	NS
rs10558975	39675051	PGAP3		G	-0.54	1.1E-5	-0.32	0.01	0.13	0.3	G ~ PGAP3↓ (1E-13); ORMDL3↓ (2E-5); GSDMB↓ (6E-5)	
rs907088	39677314	PGAP3		2	G	0.69	3.3E-7	0.32	0.02	-0.27	0.06	G ~ PGAP3↑ (1E-12); ORMDL3↑ (8E-8)
rs2517954	39687297	PGAP3			T	0.77	3.1E-9	0.25	0.08	-0.29	0.04	T ~ PGAP3↑ (9E-10); ORMDL3↑ (3E-8)
rs2904765	39692422	PGAP3-ERBB2			T	0.70	8.7E-6	0.17	0.3	-0.34	0.04	NS
rs56328874	39694273	PGAP3-ERBB2			A	-0.72	1.0E-4	0.16	0.4	0.26	0.2	NS
rs2517951	39696844	PGAP3-ERBB2	2	3	T	-0.58	1.6E-6	-0.29	0.02	0.13	0.3	T ~ PGAP3↓ (1E-13); ORMDL3↓ (2E-6); GSDMB↓ (2E-5)
rs2952155	39705465	ERBB2			T	0.72	4.6E-7	0.31	0.04	-0.23	0.1	T ~ PGAP3↑ (2E-8); ORMDL3↑ (1E-6)
rs2934967	39714125	ERBB2			G	0.79	9.9E-9	0.25	0.08	-0.29	0.05	G ~ PGAP3↑ (5E-11); ORMDL3↑ (2E-8); GSDMB↑ (4E-5); GSDMA↓ (6E-6)
rs2941520	39747477	GRB-IKZF3		4	T	0.70	1.7E-6	0.30	0.05	0.01	0.9	T ~ PGAP3↑ (2E-10); ORMDL3↑ (3E-9); GSDMB↑ (1E-6)
rs2941519	39747478	GRB-IKZF3			G	-0.36	0.01	-0.15	0.3	0.52	1.6E-4	G ~ ORMDL3↓ (5E-14); GSDMB↓ (6E-13); PGAP3↓ (5E-6); GSDMA↑ (3E-5)
rs9747973	39748854	GRB-IKZF3			C	-0.41	0.003	-0.34	0.01	0.53	1.0E-4	C ~ GSDMB↓ (2E-15); ORMDL3↓ (7E-15); GSDMA↑ (6E-7); PGAP3↓ (1E-6)
rs12450323	39816455	IKZF3			T	0.63	1.5E-4	0.43	0.01	0.13	0.4	T ~ ORMDL3↑ (1E-5); GSDMB↑ (2E-5); PGAP3↑ (2E-5)
rs114211283	39819840	IKZF3			A	1.11	3.5E-5	0.13	0.6	0.12	0.7	NS
rs62066988	39836028	IKZF3		3	T	-0.35	0.02	-0.56	1.4E-4	0.31	0.04	T ~ ORMDL3↓ (2E-6); GSDMB↓ (2E-5); GSDMA↑ (4E-5)
rs9635726	39863888	IKZF3				T	0.63	1.3E-4	0.47	0.005	0.07	0.7
rs4795397	39867492	IKZF3-ZBP2	5			G	-0.40	0.003	-0.52	1.0E-4	0.42	0.002
rs12150079	39869164	ZBP2			A	-0.38	0.01	-0.59	5.7E-5	0.32	0.03	A ~ ORMDL3↓ (3E-7); GSDMB↓ (6E-6); GSDMA↑ (7E-6)

rs11651596	39899863	<i>ZPBP2-GSDMB</i>	6	C	-0.36	0.008	-0.62	1.6E-6	0.32	0.02	C ~ ORM DL3↓ (2E-10); GSDMA↑ (3E-10); GSDMB↓ (2E-9)
rs11657449	39901588	<i>ZPBP2-GSDMB</i>		C	-0.34	0.02	-0.69	7.5E-7	0.32	0.03	C ~ ORM DL3↓ (2E-7); GSDMA↑ (7E-7); GSDMB↓ (6E-6)
rs1011082	39912261	<i>GSDMB</i>		T	-0.33	0.01	-0.51	6.6E-5	0.31	0.02	T ~ GSDMB↓ (8E-16); ORM DL3↓ (6E-13); GSDMA↑ (1E-7); PGAP3↓ (4E-7)
rs201413617	39917590	<i>GSDMB-ORM DL3</i>		G	-0.33	0.01	-0.48	1.6E-4	0.27	0.04	NS
rs4795405	39932164	<i>ORM DL3-LRRC3C</i>		T	-0.35	0.01	-0.51	1.6E-4	0.45	0.0009	T ~ GSDMA↑ (3E-14); ORM DL3↓ (1E-10); GSDMB↓ (p=6E-10)
rs9914973	39966455	<i>GSDMA</i>		C	-0.42	0.002	-0.22	0.1	0.52	1.7E-4	C ~ GSDMA↑ (9E-17)
rs3859193	39969603	<i>GSDMA</i>		A	0.31	0.02	0.13	0.3	-0.50	7.2E-5	A ~ GSDMA↓ (9E-30); GSDMB↑ (5E-7)

Note: entries with p-value<1.98x10<sup>-4</sup> were labeled in red color. β and P were correlation coefficient and p-value of eQTL analysis.

BEC: bronchial epithelial cells brushing. NS: non-significant.

\*LD was estimated with 95% confidence intervals of D' to define LD blocks of 26 SNPs for 1,016 non-Hispanic Whites (NHW) and 622 African Americans (AA) in SARP longitudinal cohort and cross-sectional cohort with WGS using Haploview.<sup>81</sup>

†eQTL of GTEx database: eQTL SNPs identified in the lung tissue (n=383) from Genotype-Tissue Expression (GTEx) database.<sup>26</sup>

↑indicated up-regulation of gene expression and ↓indicated down-regulation of gene expression.

**TABLE IV.** Correlation of the expression levels of *PGAP3*, *GSDMB*, or *GSDMA* and asthma phenotypes in SARP

RNAseq (156 BEC) in the longitudinal cohort										
Gene	Asthma Susceptibility			Asthma Severity			Number of Exacerbations (last 12 months)		$\Delta$ ACQ6 (After-Before steroid trt )	
	Healthy Controls (n=42)	Asthma (n=114)	P value	Non-severe Asthma (n=49)	Severe Asthma (n=65)	P value	Correlation Coefficient ( $\beta$ )	P value (n=114)	Correlation Coefficient ( $\beta$ )	P value (n=109)
<i>PGAP3</i>	8.81 $\pm$ 0.22	8.88 $\pm$ 0.20	0.08	8.90 $\pm$ 0.21	8.87 $\pm$ 0.20	0.33	-0.84	0.57	-0.12	0.77
<i>GSDMB</i>	9.94 $\pm$ 0.25	10.1 $\pm$ 0.32	0.05	10.1 $\pm$ 0.28	10.1 $\pm$ 0.35	0.89	2.11	0.019	-0.81	0.0008
<i>GSDMA</i>	0.50 $\pm$ 0.15	0.55 $\pm$ 0.22	0.26	0.52 $\pm$ 0.19	0.57 $\pm$ 0.24	0.29	-1.40	0.27	0.14	0.69
Microarray (155 BEC) in the cross-sectional cohort										
Gene	Asthma Susceptibility			Asthma Severity			ER or Hospitalization (last 12 months)			
	Healthy Controls (n=27)	Asthma (n=128)	P value	Non-severe Asthma (n=78)	Severe Asthma (n=50)	P value	No (n=77)	Yes (n=47)	P value	
<i>PGAP3</i>	10.8 $\pm$ 0.22	10.8 $\pm$ 0.33	0.43	10.8 $\pm$ 0.34	10.8 $\pm$ 0.31	0.63	10.8 $\pm$ 0.35	10.8 $\pm$ 0.29	0.57	
<i>GSDMB</i>	10.5 $\pm$ 0.42	10.4 $\pm$ 0.47	0.15	10.4 $\pm$ 0.45	10.4 $\pm$ 0.51	0.23	10.3 $\pm$ 0.46	10.5 $\pm$ 0.49	0.03	
<i>GSDMA</i>	6.26 $\pm$ 0.15	6.21 $\pm$ 0.13	0.02	6.21 $\pm$ 0.14	6.21 $\pm$ 0.12	0.56	6.21 $\pm$ 0.13	6.20 $\pm$ 0.13	0.41	

Note: a general linear model was used to test the correlation between gene expression levels (natural logarithm transformed in the longitudinal cohort or log2 transformed in the cross-sectional cohort) and asthma phenotypes with adjustment of age, sex, race, BMI, and batch effect.



**Table V.** Biological pathways enriched for genes with expression levels correlated with *GSDMB* expression in BEC in the longitudinal cohort

Pathway	Gene	P value (FDR)
Interferon gamma signaling	CIITA, HLA-A, HLA-B, HLA-C, HLA-F, IFNG, IFNGR2, IL20RA, IRF9, MID1, OAS2, OAS3, PML, SP110, SP140L, STAT1, SUMO1, TRIM14, TRIM22, TRIM25, TRIM26, TRIM38	2.3E-14
Interferon alpha/beta signaling	BST2, HLA-A, HLA-B, HLA-C, HLA-F, IFI27, IRF9, MX2, OAS2, OAS3, STAT1, STAT2, USP18, XAF1	2.3E-14
Antigen Presentation (Folding, assembly and peptide loading of class I MHC)	HLA-A, HLA-B, HLA-C, HLA-F, SEC24B, TAP1, TAP2, TAPBP	2.3E-14
ER-Phagosome pathway	HLA-A, HLA-B, HLA-C, HLA-F, IKBKB, PSMB9, PSMD8, PSME2, RAPSN, TAP1, TAP2, TAPBP	2.3E-14
Interferon Signaling	BST2, CIITA, HLA-F, IFI27, IFNG, IFNGR2, IL20RA, IRF9, MAPK1, MID1, MX2, NUP210, OAS2, OAS3, PML, SP110, SP140L, STAT1, STAT2, SUMO1, TRIM14, TRIM22, TRIM25, TRIM26, TRIM38, UBA7, USP18, XAF1	2.3E-14
Endosomal/Vacuolar pathway	HLA-A, HLA-B, HLA-C, HLA-F	2.3E-14
Antigen processing-Cross presentation	HLA-A, HLA-B, HLA-C, HLA-F, IKBKB, ITGB5, PSMB9, PSMD8, PSME2, RAPSN, TAP1, TAP2, TAPBP	2.3E-14
Class I MHC mediated antigen processing & presentation	ASB14, ASB4, ASB8, FBXL3, FBXO2, FBXO21, FBXO41, HLA-A, HLA-B, HLA-C, HLA-F, IKBKB, ITGB5, NARF, PJA2, POLL, PSMB9, PSMD8, PSME2, RAPSN, RBX1, RNF213, SEC24B, SIAH1, SKP1, TAP1, TAP2, TAPBP, TRIM36, TRIM39, UBA7, UBE2D2, UBE2D4, UBE2E3	3.5E-13
Immunoregulatory interactions (between a Lymphoid and a non-Lymphoid cell)	CD226, CLEC2D, HLA-A, HLA-B, HLA-C, HLA-F, RAET1E	6.3E-11
Cytokine Signaling in Immune system	ATF1, ATF2, CALM2, CIITA, CRKL, DUSP16, FASLG, HLA-A, HLA-B, HLA-C, HLA-F, IFI27, IKBKB, IL18BP, IL20RA, IL37, IL6ST, IRF9, LAMTOR3, LGALS9, LIFR, MID1, MX2, NDN, PDGFA, PML, PSME2, PTPN14, PTPN4, RBX1, SKP1, SP110, STAT1, STAT2, STAT6, TRIM14, TRIM22, TRIM25, TRIM26, TRIM38	7.9E-08
Adaptive Immune System	ACTR10, ASB4, ASB8, ASB14, BLNK, BTF3, BTN2A1, BTN2A2, BTN3A1, CALM2, CARD11, CD74, CLEC2D, DCTN3, DCTN6, FBXL3, FBXO41, GRAP2, HLA-A, HLA-B, HLA-C, IKBKB, MAP3K14, POLL, PSMD8, RAET1E, SEC24B, SIAH1, SKP1, TAP1, TAP2, TBCB, TEP1, TRIM36, TRIM39, UBA7, UBE2D2, UBE2D4, UBE2E3, ZAP70	9.7E-03

Note: pathways with false discovery rate (FDR)-adjusted p-value less than 0.05 were included.

**TABLE VI.** Genetic association and eQTL results of 6 SNPs in IRF binding site of *GSDMB* in SARP.

SNP	Position (hg38)	SNP Type	IRF Binding Sites	Allele* (MAF)	Asthma Severity†	Number of Exacerbations in 3 years‡	eQTL in BEC (n=114) Longitudinal Cohort**			eQTL GTEx database Lung Tissue (n=383)††
					OR (P)	β (P)	PGAP3 β (P)	GSDMB β (P)	GSDMA β (P)	
rs1031458	39915920	intronic	IRF4	G/T (0.45)	0.76 (0.0053)	-0.77 (0.028)	-0.36 (5.1E-3)	-0.47 (2.4E-4)	0.31 (0.018)	GSDMB↓ (1E-20) ORMDL3↓ (3E-19) GSDMA↑ (1E-14) PGAP3↓ (1E-7)
rs3902920	39918763	5'UTR	IRF1/2	T/C (0.46)	0.75 (0.0027)	-0.88 (0.012)	-0.29 (0.036)	-0.45 (0.0011)	0.27 (0.047)	NA
rs77929191	39915767	intronic	IRF4	A/G (0.0021)	0.37 (0.40)	-2.9 (0.47)	-0.44 (0.54)	-1.26 (0.078)	-0.045 (0.95)	NS
rs536439445	39918670	5'UTR	IRF1/2	A/G (0.0052)	0.57 (0.41)	-1.8 (0.53)	0.77 (0.45)	-1.40 (0.17)	0.011 (0.99)	NS
rs549170154	39918764	5'UTR	IRF1/2	C/T (0.0021)	0.68 (0.74)	5.1 (0.21)	0.20 (0.78)	-0.18 (0.80)	-0.012 (0.99)	NA
rs540139228	39918797	5'UTR	IRF1/2	G/A (0.0010)	1.3 (0.86)	-2.6 (0.52)	NA	NA	NA	NA

\*Minor allele (effect allele)/major allele (minor allele frequency).

†OR and P were odds ratio and p-value for genetic association analysis of asthma severity (426 severe vs. 531 non-severe asthma) in non-Hispanic White in SARP.

‡β and P were correlation coefficient and p-value for genetic association analysis of the number of longitudinal exacerbations due to asthma in 3 years in the longitudinal cohort in 273 asthmatics with longitudinal asthma exacerbations in non-Hispanic White in SARP.

\*\*β and P were correlation coefficient and p-value for eQTL analysis in 114 subjects with RNAseq of bronchial epithelial cells in SARP longitudinal cohort.

††eQTL of GTEx database: eQTL SNPs identified in the lung tissue (n=383) from Genotype-Tissue Expression (GTEx) database.<sup>26</sup> ↑indicated up-regulation of gene expression and ↓indicated down-regulation of gene expression. NA: non-available and NS: non-significant.

GWAS of Asthma Susceptibility & Allergy & Autoimmune Diseases (GWAS catalog)

*PGAP3*, *ERBB2*, *IKZF3*, *ZPBP2*, *GSDMB*, *ORMDL3*, *GSDMA*, *PSMD3* (n=8)

Genetic Association Analysis of Asthma Severity & Asthma Exacerbations (SARP)

*PGAP3*, *ERBB2*, *IKZF3*, *ZPBP2*, *GSDMB*, *ORMDL3*, *GSDMA* (n=7)

eQTL Analysis in Bronchial Epithelial Cells (BEC) (SARP) &  
Replicated eQTL Analysis in BEC (SARP) & in Lung Tissue (GTEx) &  
Conditional eQTL Analysis & Colocalization Analysis (SARP)

*PGAP3*↑ *GSDMB*↑ *GSDMA*↓ (n=3)

Correlation Analysis of Gene Expression (*PGAP3*, *GSDMB*, *GSDMA*) and Asthma  
Phenotypes in BEC & Replicated Correlation Analysis in BEC (SARP)

*GSDMB*↑ (n=1)


Pathway Analysis of Genes with Expression Levels Correlated with *GSDMB*  
Expression Levels in BEC & Replicated Pathway Analysis in BEC (SARP)

Antiviral Pathways  
(Interferon  $\alpha/\beta/\gamma$ , class I MHC)


Interferon Regulatory Factor (IRF) Binding Site (ENCODE) &  
Genetics Association and eQTL Analyses of SNPs in *GSDMB* (SARP)

rs1031458 (Intron 2 in *GSDMB*; IRF4 Binding Site)  
rs3902920 (5'UTR in *GSDMB*; IRF1/2 Binding Site)

A



B



# UCSC Genome Browser on Human Dec. 2013 (GRCh38/hg38) Assembly


move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x 100x

chr17:39,626,924-40,017,813 390,890 bp.


enter position, gene symbol, HGVS or search terms


go

chr17 (q12-q21.1) p13.3 p13.2 p13.1 17p12 17p11.2 17q11.2 17q12 q21.31 17q22 23.2 24.2 q24.3 q25.1 17q25.3






















# UCSC Genome Browser on Human Dec. 2013 (GRCh38/hg38) Assembly

move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x 100x

chr17:39,904,500-39,918,900 14,401 bp. enter position, gene symbol, HGVS or search terms

go [We're Hiring!](#)

chr17 (q21.1) 17p13.3 17p13.2 17p13.1 17p12 17p11.2 17q11.2 17q12 17q21.2 17q21.31 17q21.32 17q21.33 17q22 17q23.2 17q24.1 17q24.2 17q24.3 17q25.1 17q25.3




go **We're Hiring.**

move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x 100x

chr17:39,918,440-39,918,810 371 bp. enter position, gene symbol, HGVS or search terms

go






# UCSC Genome Browser on Human Dec. 2013 (GRCh38/hg38) Assembly

move <<< << < > >> >>> zoom in 1.5x 3x 10x base zoom out 1.5x 3x 10x 100x

chr17:39,915,640-39,915,960 321 bp. enter position, gene symbol, HGVS or search terms

go

[We're Hiring!](#)



## chr17:39,626,924-40,017,813 390,890 bp. chr17:39,626,924-40,017,813

